RecipharmCobra Biologics Announces Patent for Novel Antibiotic-Free Plasmid Maintenance System
The invention of oriSELECT puts RecipharmCobra in the unique position of owning the only two plasmid maintenance systems, including ORT (Operator-Repressor Titration), that are free of the burden of expressed selectable marker genes.
Simon Saxby, Vice President, Biologics commented: “RecipharmCobra is continually looking at the application of state-of-the-art genetic engineering methods in order to improve regulatory compliance, which is continually becoming more stringent, and to ensure maximum efficiencies and cost benefits for our customers. Antibiotic resistance gene transfer is an area of concern where oriSELECT and ORT can provide a state-of-the-art solution.”
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.